source
- AstraZeneca halts Phase 3 lung cancer trial of bispecific antibody volrustomig after interim data miss survival goalAstraZeneca announced termination of the Phase 3 study of its experimental bispecific antibody volrustomig in non‑small cell lung cancer. An interim data review by trial monitors indicated the dru…
- FDA releases first updated guidance in 27 years on container and closure systems for drugs and biologicsThe FDA announced a draft guidance that updates the agency’s recommendations for evaluating container and closure systems used in the packaging of new drugs and biologics. This revision is the fir…